使用微囊化丝裂霉素C评估肾细胞癌的治疗性动脉栓塞术。

Evaluation of therapeutic arterial embolization in renal cell carcinoma using microencapsulated mitomycin C.

作者信息

Nemoto R, Kato T, Iwata K, Mori H, Takahashi M

出版信息

Urology. 1981 Apr;17(4):315-9. doi: 10.1016/0090-4295(81)90253-3.

Abstract

The therapeutic arterial embolization in the case of renal cell carcinoma using microencapsulated mitomycin C (MMC) was investigated by an angiographic evaluation in comparison with nonencapsulated MMC. The Gelfoam embolization supplemented with nonencapsulated MMC could not necessarily prevent the recanalization and collateral circulation, while the Gelfoam embolization supplemented with microencapsulated MMC completely or considerably eliminated the revascularization with a distinct advantage in this degree. Moreover, peripheral blood MMC level after the embolization using microencapsulated MMC was reduced to 39 per cent of that after nonencapsulated MMC infusion. The result was consistent with the previous experiments, indicating that the transcatheter infusion of microencapsulated MMC is the therapeutic arterial embolization of the tumor-supplying vessels together with regional anticancer chemotherapy. Further clinical application to various malignancies is in progress.

摘要

通过血管造影评估，对使用微囊化丝裂霉素C（MMC）治疗肾细胞癌的动脉栓塞疗法与未囊化MMC进行了比较研究。补充未囊化MMC的明胶海绵栓塞术不一定能防止再通和侧支循环形成，而补充微囊化MMC的明胶海绵栓塞术能完全或显著消除血管再生，在这方面具有明显优势。此外，使用微囊化MMC栓塞后外周血MMC水平降至未囊化MMC输注后水平的39%。该结果与先前的实验一致，表明经导管输注微囊化MMC是肿瘤供血血管的治疗性动脉栓塞术，同时也是区域抗癌化疗。目前正在对各种恶性肿瘤进行进一步的临床应用研究。